Introduction
Current cancer chemotherapy targets proliferating and metabolically active cancer cells and efficiently reduces the tumor load. However, frequent relapses suggest the persistence of residual cancer stem cells that escaped treatment possibly due to a protective microenvironment that blunts their chemosensitivities (1) (2) (3) . The reliance of cancer stem cells on their microenvironments and on non-cell-autonomous pathways (3) together with the failure of mainstream chemotherapy in a significant proportion of patients points to an urgent need for novel drug screening strategies designed to target cancer stem cells in their niche.
Recent evidence based on ultradeep sequencing of targeted genomic regions in acute leukemias revealed the existence of longlasting preleukemic hematopoietic stem cells within the bulk of leukemic cells that serve as a reservoir for disease progression (4, 5) . While these cells are believed to resist therapy, direct evidence for their distinctive chemosensitivities compared with leukemic blasts remains to be documented. In addition, treatment is limited by indiscriminate toxicity toward normal hematopoietic stem cells (HSCs). Therefore, the current challenge is to specifically target these preleukemic stem cells (pre-LSCs) that represent an extremely rare subpopulation in patients (4) (5) (6) (7) and are not easily amenable to high-throughput screening (HTS) for novel drug discovery.
Acute lymphoblastic leukemia (ALL) is the most frequent pediatric cancer. T cell ALL (T-ALL), representing 15%-20% of ALL, can be classified into major molecular subgroups characterized by overexpression of oncogenic transcription factors (8, 9) that include SCL/TAL1, a member of the basic helix-loophelix (bHLH) family, and LMO1 and LMO2, two LIM-only proteins (10) . We and others have previously shown that oncogenic transcription factors in acute leukemia reprogram non-stem cell populations into aberrantly self-renewing pre-LSCs (7, (11) (12) (13) (14) . Using transgenic mouse models expressing the human SCL and LMO1 oncogenes in the thymus (15, 16) , we showed that pre-LSCs remain dependent on physiological signaling from the microenvironment, specifically on activation of the NOTCH1/MYC axis (14) . Our observations underscore the critical importance of a niche-based assay for pre-LSCs, to allow for the discovery of new classes of antileukemic drugs beyond those that have been identified so far using standard cell line screening. A challenge in HTS is the necessary miniaturization Current chemotherapies for T cell acute lymphoblastic leukemia (T-ALL) efficiently reduce tumor mass. Nonetheless, disease relapse attributed to survival of preleukemic stem cells (pre-LSCs) is associated with poor prognosis. Herein, we provide direct evidence that pre-LSCs are much less chemosensitive to existing chemotherapy drugs than leukemic blasts because of a distinctive lower proliferative state. Improving therapies for T-ALL requires the development of strategies to target pre-LSCs that are absolutely dependent on their microenvironment. Therefore, we designed a robust protocol for high-throughput screening of compounds that target primary pre-LSCs maintained in a niche-like environment, on stromal cells that were engineered for optimal NOTCH1 activation. The multiparametric readout takes into account the intrinsic complexity of primary cells in order to specifically monitor pre-LSCs, which were induced here by the SCL/TAL1 and LMO1 oncogenes. We screened a targeted library of compounds and determined that the estrogen derivative 2-methoxyestradiol (2-ME2) disrupted both cellautonomous and non-cell-autonomous pathways. Specifically, 2-ME2 abrogated pre-LSC viability and self-renewal activity in vivo by inhibiting translation of MYC, a downstream effector of NOTCH1, and preventing SCL/TAL1 activity. In contrast, normal hematopoietic stem/progenitor cells remained functional. These results illustrate how recapitulating tissue-like properties of primary cells in high-throughput screening is a promising avenue for innovation in cancer chemotherapy. A and B) Pre-LSCs are more resistant to the treatment than leukemic cells. Pre-LSCs or fully transformed SCL-LMO1 leukemic blasts were cocultured on OP9-DL1 stromal cells and treated with camptothecin (Campto, A, left panel), doxorubicin (DOXO, A, right panel), or dexamethasone (DEXA, B) for 3 days. Viable T cells were assessed by FACS (mean ± SEM compared with controls, n = 6, *P ≤ 0.05). Representative of 2 independent experiments. (C) Inverse correlation between pre-LSC gene signature (14) and tumor load in Cd3e -/-SCL-LMO1 T-ALLs. Data from RNA sequencing of Cd3e -/-SCL-LMO1 T-ALLs were ranked according to the tumor load (Supplemental Figure 1A ). (D) Gene set enrichment analysis for genes that are upregulated in leukemic blasts compared with pre-LSCs. Top panel: The top 7 gene ontology categories significantly enriched in T-ALL blasts (FWER P < 0.03). Bottom panel: Enrichment plots. (E) Pre-LSCs or leukemic blasts (5 × 10 4 cells, CD45.2) from Cd3e -/-SCL tg LMO1 tg mice or WT thymocytes were transplanted into recipient mice (CD45.1). Shown are the percentage of donor T cells (% CD45.2 + Thy1.2 + ) per mouse analyzed 3 and 6 weeks later. Horizontal lines, median of thymic engraftment. (F and G) Pre-LSCs exhibit low cell division frequency and are outcompeted by leukemic cells in vitro. SCL-LMO1 leukemic cells (GFP -) and pre-LSCs (GFP + ) were mixed in equal proportion and cultured for 3 days on OP9-DL1; GFPand GFP + cells were analyzed before (gray curve) and after (black curve) coculture (F, n = 3). The numbers of divisions per field of observation during 20 hours (G, top panel, n = 4) and each individual division observed at the indicated times in a total of 6 fields of view (G, bottom panel, n = 5-23) were then compared between GFPand GFP + cells by time-lapse imaging (20 hours initiating event is the establishment of an aberrant population of pre-LSCs found in both healthy and leukemic twins, with additional transforming event(s) in the leukemic patient (7) . The identification of activating NOTCH1 mutations in over 60% of T-ALL patient samples in all molecular subgroups (17) rapidly led to the design of high-potency γ-secretase inhibitors (GSIs) targeting NOTCH1 signaling. GSIs are well tolerated with staggered dosing of a stromal-based coculture assay into a reproducible assay with a quantitative readout. At the cellular level, these pre-LSCs serve as a reservoir for acquisition of Notch1 gain-of-function mutations (16) that recapitulate those identified in the human disease (17) . Therefore, the mouse model closely mimics the leukemogenic process in humans, initially reported in monochorionic twins in which the Generation of an optimal MS5-DL4 stromal cell line for pre-LSC viability. Following DL4 gene transfer, MS5 stromal cells were assessed for DL4 surface expression levels. Three MS5 subclones were purified according to levels of DL4 expression (low, medium, and high) (A). DN3 preleukemic SCL tg LMO1 tg thymocytes were cocultured with MS5-CTL or MS5-DL4 lo , -DL4 med , or -DL4 hi stromal cells during 5 days, and the absolute number of DN3 cells was assessed using FACS. Each dot represents an individual well, and dashed lines represent the mean for each condition (B). (C) Purified DN3 WT and preleukemic SCL tg LMO1 tg thymocytes were cocultured with MS5-DL4 lo stromal cells. DN3-derived thymocytes were immunophenotyped 5 days later using the CD4, CD8, CD25, and CD44 markers. (D) Miniaturized coculture system for HTS-FACS in 384-well plate. The proportion of DN3 (left panel) and DP (right panel) thymocytes was then assessed using HTS-FACS, and assay reproducibility was calculated. Each dot represents an individual well. Solid lines and dashed lines represent the mean and 3-fold the SD, respectively. The Z′ factor is a statistical measure of the robustness of the HTS assay (ideally between 0.5 and 1). Representative of 3 independent experiments. (E and F) DN3 preleukemic SCL tg LMO1 tg thymocytes were cocultured with MS5-DL4 lo stromal cells for 5 days in the presence or absence (Vehicle) of γ-secretase inhibitor (GSI, 1 μM), and the absolute number of DN3 cells was assessed using HTS-FACS. Representative FACS analysis of DN population is shown (E) together with assay reproducibility (F). jci.org Volume 126 Number 12 December 2016 than pre-LSCs, hence their higher sensitivities to topoisomerase inhibitors. The enrichment in cell cycle genes was manifested in vivo by the kinetic of thymic reconstitution after transplantation into sublethally irradiated congenic recipient mice ( Figure  1E ). Within 3 weeks, T-ALL blasts rapidly and massively invaded the thymus ( Figure 1E ), spleen, and BM (Supplemental Figure  1B) , while pre-LSCs induced a modest and heterogeneous thymic reconstitution at 3 weeks after transplantation and even at 6 weeks, without engrafting other organs. As expected, WT thymocytes did not engraft ( Figure 1E and Supplemental Figure 1B ). To directly address the question of whether leukemic blasts are more competitive than self-renewing pre-LSCs, we set up an equal-split competition in which equal proportions (50%) of GFP + pre-LSCs from SIL-SCL Lck-LMO1 double-transgenic mice (SCL tg LMO1 tg mice), which express the human SCL and LMO1 genes, and non-GFP leukemic cells were cultured on OP9-DL1 ( Figure 1F ). Within 3 days, T-ALL blasts outcompeted pre-LSCs in culture as observed by the 3-fold reduction of the proportion of GFP + pre-LSCs ( Figure  1F ). Furthermore, time-lapse imaging (Supplemental Figure 1C ) of this equal-split competitive assay performed 6 hours after plating revealed that the division rate of leukemic cells was 4 times higher than that of pre-LSCs ( Figure 1G ). Together, our results demonstrate that pre-LSCs have a low proliferative status and are more resistant than leukemic cells to current chemotherapeutic drugs that target proliferating cells, such as doxorubicin. Based on the evidence that pre-LSCs caused relapse (6) , these cells represent the prime target for new drug development.
Design of a high-throughput screening protocol based on pre-LSC viability in a niche-like microenvironment. Several essential parameters needed to be integrated into the design of a robust pre-LSCbased assay for high-throughput screening (HTS). First, pre-LSCs are extremely rare in leukemic patient samples, requiring extensive purification by flow cytometry and ultradeep sequencing to reveal mutations that occur in these cells (4, 24) . This is because pre-LSCs are much less competitive than leukemic blasts, as shown above, and are highly diluted in the leukemic mass at the time of overt leukemia. We took advantage of the preleukemic stage in transgenic mouse models to have unrestricted access to a reproducible source of pre-LSCs. These cells were harvested at weaning, long before the acquisition of secondary mutations and leukemia onset (16) . Second, we opted for a phenotypic screen for several reasons. Given the molecular diversity of T-ALL, we reasoned that a phenotypic screen using primary pre-LSCs has a higher likelihood of identifying small-molecule inhibitors of selfrenewal, rather than targeting the diversity of oncogenes in the 5 molecular subgroups of T-ALL (10, 26) . In addition, pre-LSCs in 3 different genetic models of T-ALL of the bHLH subgroup are DN3 cells (12, 14, 27) , and rely on the same self-renewal genes for maintenance in vivo (12, 14, 27) , reinforcing the suitability of this population as target. Moreover, a multiparametric phenotypic screen takes into account the heterogeneity of primary cells (14, 28) and allows for a quantitative assessment of this specific subset of cells based on surface phenotype.
Finally, we previously showed that pre-LSCs conserve their dependence on the thymic microenvironment and require coculture on OP9 stromal cells expressing delta-like 1 (DL1) for survival in culture (14) , much like their normal counterparts (29) . We in several phase I clinical trials (18, 19) . Nonetheless, efficient antileukemic activity might require sustained administration, which in turn could be a limiting factor (20) . Interestingly, MYC is an essential downstream effector of NOTCH1 in T-ALL (21, 22) , and decreasing Myc expression via a BRD4 inhibitor effectively killed leukemia-initiating cells (23) .
As discussed above, pre-LSCs are more genetically and phenotypically stable (14) than leukemia-propagating cells, which have acquired different sets of secondary mutations (16, 24) . Importantly, we provided genetic evidence that self-renewal activity is a major determinant of leukemogenesis (14) , further underscoring the importance of pre-LSC-based screening to identify novel antileukemic compounds. A major advantage of the mouse model is to provide unrestricted access to pre-LSCs (14) .
Here, we demonstrate that pre-LSCs are much less sensitive to current treatment than the leukemic bulk, underscoring the importance of novel therapeutic development targeting pre-LSCs. We built on mechanistic insight gained in our previous work (14) to develop a robust protocol for a phenotypic screen with SCL-LMO1-induced pre-LSCs cultured within their niche-like microenvironment. Using FDA-approved compounds and drug-like small molecules, we identified 2-methoxyestradiol (2-ME2) as a new promising drug that abrogates pre-LSC viability and selfrenewal activity by inhibiting MYC translation and SCL accumulation, thereby antagonizing cell-autonomous as well as non-cellautonomous pathways.
Results
Pre-LSC low chemosensitivity and low proliferation rate. Pre-LSCs are believed to be chemoresistant and to drive relapse (4, 24), although direct evidence for differential chemosensitivity between leukemic blasts and pre-LSCs remains to be documented. We took advantage of genetic mouse models to directly address the distinctive properties of pre-LSCs compared with fully transformed cells using in vitro and in vivo approaches. We previously showed that Cd3e +/+ or Cd3e -/-DN3 thymocytes are the only pre-LSCenriched population in mice expressing SCL-LMO1 (14), hereafter "pre-LSCs." First, we compared the response of pre-LSCs and T-ALL blasts to 2 commonly used inhibitors of DNA replication, doxorubicin and camptothecin ( Figure 1A ). Dose-response curves indicate that leukemic cells are 10-to 20-fold more sensitive to the 2 drugs than pre-LSCs in vitro. Moreover, this difference was also observed with dexamethasone (DEXA; Figure 1B ), a glucocorticoid often used for stratification and treatment of childhood and adult T-ALL (25) . We conclude that pre-LSCs are poorly responsive to current chemotherapeutic drugs.
We next analyzed by RNA sequencing the transcriptomes of 3 SCL-LMO1 T-ALLs taken at different stages of leukemia development, as assessed by the tumor load. Strikingly, we found that the pre-LSC stem cell gene signature (14) was inversely correlated with the tumor load, supporting the view that pre-LSCs were progressively outcompeted by more aggressive leukemic cells ( Figure  1C and Supplemental Figure 1A ; supplemental material available online with this article; doi:10.1172/JCI86489DS1). Conversely, the top gene ontology categories associated with acute leukemia compared with the preleukemic stage are mitosis and cell cycle ( Figure 1D ), indicating that leukemic blasts are more proliferative jci.org Volume 126 Number 12 December 2016
appropriate for a robust chemical HTS assay that requires several days of drug exposure. We generated MS5 stromal cell lines expressing different levels of the most physiological NOTCH1 ligand, delta-like 4 (DL4) (31, 32), for coculture with SCL tg LMO1 tg therefore designed a miniaturized coculture assay for pre-LSC viability in their "habitat." To this end, we replaced OP9 cells, which need replating every 3 days, with MS5 stromal cells, which can be maintained for at least 7 days in culture (30) and are more The inhibition of pre-LSC viability was calculated for each compound (GSI set as 100% and DMSO as 0%; average pre-LSC viability: 0.4%). The top 5% (n = 96) of hits were selected. (C) Clustering of 44 selected compounds by structural similarities using the ChemMine tool (http://chemmine.ucr.edu/). The multidimensional scaling algorithm maps a compound described by its chemical structure into a 3D space and where neighbor compounds exhibit similar molecular structure. The axes (D1, D2, and D3) refer to the dimensions generated by the multidimensional scaling. Black arrow identifies 2-ME2 and gray arrow DEXA. MTDs, microtubuletargeting drugs. (D) 2-ME2 is the only MTD that does not affect the viability of human HSCs. Human CD34 + peripheral blood was collected from cord blood cells and treated with the indicated MTDs at 1 μM during 1 week as described previously (38) . Numbers pre-LSCs ( Figure 2A ). We found that MS5-DL4 lo cells sustained viability of SCL tg LMO1 tg pre-LSCs more efficiently than MS5 expressing higher DL4 levels ( Figure 2B ). We therefore selected MS5-DL4 lo (hereafter "MS5-DL4") for further experiments.
These coculture conditions favored the differentiation of purified WT DN3 thymocytes to the double-positive (DP) stage within 5 days ( Figure 2C ). In contrast, SCL-LMO1-expressing pre-LSCs remained blocked at the DN3 stage during the same time frame ( Figure 2C ), reproducing the differentiation arrest observed in vivo (33, 34) . Similar results were observed when the assay was miniaturized in 384-well format ( Figure 2D ). Finally, as proof of concept for the screen, cultures were exposed to GSI at 1 μM or to the vehicle alone ( Figure 2 , E and F). The drug was added 12 hours after seeding to allow for pre-LSC-stromal interaction before treatment. GSI strongly and reproducibly killed pre-LSCs as reported (14), with a robust Z′ factor. By taking into account the heterogeneity of primary cells (14, 28) and the necessity of nichelike microenvironments (14), the designed phenotypic screen allows for a quantitative assessment of pre-LSCs. We therefore conclude that the assay is suitable for HTS. Small-molecule screening and identification of an inhibitor of pre-LSC self-renewal activity. Using the above protocol, we screened a library of 1,904 compounds on pre-LSC viability ( Figure 3, A Figure 2 ). The majority of tested compounds had no effect on pre-LSC viability, underscoring the selectivity of the assay and the specificity of the hits. We selected the top 5% of hits that reduced the viability of pre-LSCs ( Figure 3B , range of 45%-100% inhibition). While our assay conditions enable the identification of potential inducers of differentiation ( Figure 2D and Supplemental Figure 2 ), no compound was found to overcome the DN to DP differentiation blockade imposed by SCL-LMO1. We then applied 3 criteria to filter the viability hits. First, compounds were clustered according to structural similarities (http://chemmine.ucr.edu/). Second, we determined compound selectivity by comparing our results with those obtained in a screen of 20 primary acute myeloid leukemia (AML) specimens (Supplemental Table 1 ), based on the premise that pri- group included compounds of the phenothiazine family ( Figure  3C and Supplemental Table 2 ) that were recently identified in a screen on MYC-induced T-ALL in zebrafish (35) , demonstrating the convergence of 2 functional screens, 1 based on whole-animal and the other on organotypic cultures of primary cells. Interestingly, glucocorticoids and phenothiazines with the exception of perphenazine (35) mostly spared the AML samples that were tested (Supplemental Figure 3) , indicating the discriminatory power mary human AML cells are significantly different from T-ALL. Third, we searched for compounds that spare normal hematopoietic stem/progenitor cells (HSPCs). Among the viability hits, 42 compounds clustered in 3 major groups ( Figure 3C and Supplemental Table 2 ). The first group included 15 glucocorticoids, well-known inducers of thymocyte apoptosis ( Figure 3C and Supplemental Table 2 ), in particular DEXA, which is currently used in T-ALL treatment. The second 2-ME2 did not affect the numbers of Lin -CD34 + cells compared with vehicle-treated control cultures ( Figure 3D ). 2-ME2 is an estrogen derivative that does not bind the estrogen receptor (ER) (36) , and estrogens impaired pre-LSCs at micromolar concentrations only, well outside their bioactive range (Supplemental Figure 4A) , indicating an ER-independent mechanism. Rather, 2-ME2 is an MTD (36) . Dose-response curves of 2-ME2 on SCL tg LMO1 tg pre-LSCs and normal DN3 thymocytes revealed IC 50 of 570 nM and 2 μM, respectively ( Figure  3E ), suggesting that the SCL-LMO1 oncogenes sensitize DN3 of our screening strategy. The whole library included 14 microtubule-targeting drugs (MTDs), and all were active in our assay (Figure 3C and Supplemental Table 2 ). Strikingly, 2-methoxyestradiol (2-ME2) (36) exhibits structural differences from other MTDs suggesting distinctive properties ( Figure 3C ). Indeed, 2-ME2 is the only MTD for which we observed a differential response in AML cells (Supplemental Figure 3) . Finally, MTDs have well-known toxicities toward HSPCs (37) . When tested against purified human Lin -CD34 + cells from normal cord blood (38) , all MTDs except 2-ME2 totally inhibited cell viability ( Figure 3D ). Interestingly, Similarly, we found that 2-ME2 decreased endogenous SCL protein levels in the SCL + JURKAT T-ALL cell line, starting at 4-6 hours after treatment ( Figure 4F ), exactly as observed with transfected SCL in HeLa cells (Figure 4 , D and E). Finally, our immunofluorescence approach confirmed that 2-ME2 decreases SCL without modifying histone H3 nuclear expression levels ( Figure  4 , G and H). 2-ME2 is a microtubule depolymerizing agent (43) . To assess the possibility that decreased SCL protein levels could be secondary to the perturbation of microtubule dynamics, we treated JURKAT T cells with colchicine, a well-characterized microtubule depolymerizing drug. While colchicine also inhibited cell growth (Supplemental Figure 7A) , this occurred in the absence of a noticeable effect on SCL protein levels (Supplemental Figure  7B ). Together, these results demonstrate that 2-ME2 impairs SCL expression via a colchicine-independent mechanism.
2-ME2 targets 2 pathways: inhibition of SCL and MYC. Resistance to glucocorticoids is an adverse prognostic factor in T-ALL both at presentation and in relapse (44) . We found that 2-ME2 induced apoptosis (Supplemental Figure 8A, Figure 8D) , indicating that the activity of 2-ME2 is cortico-independent.
Consistent with the reported dependence of JURKAT cell viability on SCL (45), we observed that SCL protein expression in JURKAT cells ( Figure 5B ) was inhibited by 2-ME2 in a dosedependent manner ( Figure 5C ) in exactly the same range as cell growth inhibition (~500 nM). This was associated with the downregulation of SCL target gene NKX3.1 (ref. 45 and Supplemental Figure 8E , left panel), while SCL mRNA levels were not modified by 2-ME2, as observed in pre-LSCs.
We previously showed that the self-renewal node in pre-LSCs depends not only on the SCL oncogene but also on the NOTCH1/ MYC axis (14), a non-cell-autonomous pathway triggered by Deltalike NOTCH1 ligand. Importantly, 2-ME2 did not affect NOTCH1 target genes including Myc in pre-LSCs (Supplemental Figure 9A) , ruling out the possibility that 2-ME2 could affect a general mechanism of NOTCH1 activation triggered by ligand endocytosis (46) . In contrast, 2-ME2 decreased MYC protein levels in pre-LSCs (Supplemental Figure 9B ). Interestingly, all tested T-ALL cell lines exhibit elevated MYC protein levels ( Figure 5B and Supplemental Figure 9C ), which were nearly abrogated by 2-ME2 ( Figure 5 , C and D), whereas MYC mRNA levels were unaffected (Supplemental Figure 8E , right panel). Strikingly, this inhibitory activity was not observed with 2 other factors controlling the self-renewal node in normal HSCs, HOXA9 and HOXB4, or with the SCL protein partner E2A ( Figure 5E ). Together, these results indicate a selective and previously unreported inhibitory effect of 2-ME2 on SCL and MYC protein levels.
Decreased SCL and MYC protein levels were not due to protein degradation, since 2-ME2 did not modify SCL and MYC halflives (t 1/2 ), as determined by cycloheximide chase in all 3 T-ALL thymocytes to 2-ME2. Furthermore, we observed that the nontoxic doses of 2-ME2 did not affect the capacity of WT DN3 thymocytes to generate DP cells in vitro (Supplemental Figure 4B) , indicating that 2-ME2 did not block normal T cell differentiation within the tested range. In addition, we excluded the possibility that decreased pre-LSC viability could be secondary to stromal cell failure, since MS5-DL4 cell viability as well as DL4 surface expression was not affected by 2-ME2 at concentrations as high as 10 μM ( Figure 3F ).
2-ME2 exhibits structural similarity to DEXA ( Figure 3C ). We therefore compared their activities on the self-renewal of pre-LSCs following in vitro treatments with 1 μM 2-ME2 or 5 nM DEXA (Supplemental Figure 5A ), corresponding to 75% inhibition in vitro ( Figure 3E and Figure 1B) . Pre-LSC frequency and activity were quantitatively assessed in vivo, by transplantation in irradiated congenic mice in limiting dilution assays (Supplemental Figure 5A ). As shown in Figure 3G (and Supplemental Figure 5B ), there was a striking difference between DEXA and 2-ME2. Even though both compounds were used at a dose of 75% inhibition in vitro, SCL tg LMO1 tg pre-LSCs fully recovered from DEXA treatment in culture and their self-renewal activity in vivo was not altered, concurring with the view that pre-LSCs are spared by current treatment (4, 24) . In contrast, 2-ME2 reduced pre-LSC frequency 10-fold ( Figure 3G and Supplemental Figure 5 ) and is therefore a drug candidate for T-ALL treatment.
2-ME2 inhibits SCL accumulation and transcriptional activity. At the molecular level, 2-ME2 but not DEXA decreased the expression of the SCL-dependent self-renewal genes (14) Lyl1 and Hhex without affecting mRNA levels of SCL ( Figure 4A ). Since pre-LSC self-renewal activity depends on the capacity of SCL to activate transcription (14) , we next addressed the question of whether 2-ME2 inhibits SCL transcription activity, using a quantitative reporter assay (39, 40) . We observed that 2-ME2 but not DEXA inhibited SCL activity in transient transcription assays (Figure 4B) , consistent with the suppression of endogenous SCL target genes in pre-LSCs ( Figure 4A ). These results concur with our functional studies ( Figure 3G ) and indicated that 2-ME2 inhibits pre-LSC self-renewal activity via inhibition of SCL.
Recent evidence suggests an important nonmitotic function of 2-ME2, in preventing the nuclear accumulation of transcription factors or DNA repair proteins (41, 42) . We therefore quantitated SCL at the single-cell level by flow cytometry and found that 2-ME2 caused a dose-dependent inhibition of the human SCL oncoprotein in SCL tg LMO1 tg pre-LSCs ( Figure 4C ). We examined the fate of the SCL protein by live cell imaging throughout the time exposure to 2-ME2. To this end, we delivered SCL-GFP into HeLa cells. We then followed GFP expression in individual cells in the presence or absence of 2-ME2 for 16 hours, a time point chosen based on HeLa full viability in drug-treated cultures (Supplemental Figure 6A ). SCL-GFP expression in the nucleus of 2-ME2treated cells decreased steadily compared with that in untreated cells (Figure 4 , D and E, top panels, and Supplemental Figure 6B ). In contrast, 2-ME2 treatment of HeLa cells stably expressing the nuclear protein histone H2B-RFP did not modify the level of RFP expression during the same time lapse (Figure 4 , D and E, bottom panels, and Supplemental Figure 6C) , showing that 2-ME2 specifically targets SCL accumulation. jci.org Volume 126 Number 12 December 2016
2-ME2-treated HSPCs remain functional. Finally, in vitro treatment with 2-ME2 for 4 days was sufficient to alter pre-LSC activity ( Figure 3G ), while normal HSPCs (KSL) retained self-renewal activity ( Figure 6G ) and multipotency (Supplemental Figure 11C ) in serial transplantation assays. Therefore, this preclinical model of T-ALL indicates that normal HSPCs remain functional after in vivo exposure to 2-ME2, concurring with the reported lack of myelosuppression in clinical trials (36) . Similarly, normal T cells were at least 4-fold less sensitive to 2-ME2, corresponding to an inability to downregulate MYC. In contrast, 2-ME2 reduced T-ALL blasts, leukemia-propagating cells, and pre-LSCs, revealing a significant difference in chemosensitivity between normal cells and preleukemic/leukemic cells. Primary human T-ALLs are sensitive to 2-ME2. Xenograft models of human T-ALL mimic disease relapse (52) and represent a powerful preclinical tool to directly test drug efficacy on primary leukemia cells in vivo (28) . Purified leukemic blasts from 2 T-ALL patients (14H025 and 14H148; Supplemental Table 3 ) were transplanted and expanded into immunocompromised NOD.Cg-Prkdc scid Il2rg tmWjl /SzJ (referred to here as NSG) mice ( Figure 7A ) to test their sensitivities to 2-ME2 both in vitro and in vivo.
In vitro, both patient samples were sensitive to 2-ME2 treatment in a dose-dependent manner but resistant to DEXA ( Figure  7B) . At the molecular level, patient 14H025 exhibited SIL-TAL1 chromosomal rearrangement and patient 14H148 did not (Supplemental Figure 12A and Supplemental Table 4 ). 2-ME2 treatment efficiently downregulated SCL protein levels in the SIL-TAL1 patient sample 14H025 ( Figure 7C) , associated with the inhibition of 2 SCL-dependent target genes, LYL1 and NKX3.1 (45) ( Figure  7D, left panel) . In contrast, LYL1 remained unaffected in the other patient sample, while NKX3.1 was decreased via an SCL-independent mechanism ( Figure 7D, right panel) . MYC protein expression was detectable in both patient samples despite the absence of NOTCH1 mutations and of MYC rearrangement (Supplemental Table 4 ). Interestingly, MYC was decreased by 2-ME2 treatment in vitro in both patient samples ( Figure 7C) , associated with the inhibition of the well-established MYC target gene ODC (reviewed in ref. 53) ( Figure 7D ). These observations indicate that 2-ME2 inhibits SCL and MYC functions in primary human T-ALL samples, as observed in the mouse model.
Finally, mice were transplanted and monitored for engraftment before treatment with 2-ME2 using osmotic minipumps ( Figure 7E ). Within 7 days, both samples engrafted in the BM with dissemination in the spleen, and 14H148 engrafted in the peripheral blood as well (Supplemental Figure 12B) . Strikingly, treatment with 2-ME2 downregulated SCL and MYC protein levels in vivo (Supplemental Figure 12C ) and prevented T-ALL progression by significantly reducing the leukemic burden in the BM, spleen ( Figure 7F ), and peripheral blood (Supplemental Figure 12B ) of recipient mice.
Together, these results indicate that 2-ME2 exhibits antileukemic activity in primary human T-ALL blasts.
Discussion
In the present study, we bring evidence that pre-LSCs are more chemoresistant than leukemic blasts to conventional therapies because of their low proliferation rate. We developed a robust heterotypic assay for chemical screening of primary pre-LSCs in cell lines ( Figure 5F and Supplemental Figure 9D ). We therefore examined the possibility that 2-ME2 affects SCL and MYC translation. First we observed that the p70 ribosomal S6 kinase (S6K), a key downstream effector of mTORC1 signaling pathway (47) , was active in all T-ALL cell lines ( Figure 5G ). Interestingly, 2-ME2 inhibits S6 phosphorylation in KOPTK1 and P12-ICHIKAWA and to a lesser extent in JURKAT cells ( Figure 5G) , indicating that 2-ME2 inhibits the mTORC1 pathway. Indeed, the translation of MYC mRNA was previously shown to be highly mTORC1-sensitive because of a long and structured 5′-UTR (48) . By metabolic labeling with 35 S-methionine ( Figure 5H and Supplemental Figure 9E ), we found that 2-ME2 strongly decreased MYC translation ( Figure  5H, right panel) . These results reveal an unsuspected mechanism of 2-ME2 in inhibiting MYC translation. Since SCL translation was not significantly affected by 2-ME2 ( Figure 5H, left panel) , we infer that MYC and SCL translation has differential dependence on mTORC1 signaling.
2-ME2 kills leukemic blasts without affecting viability of normal HSPCs. We next showed that 2-ME2 inhibits SCL and MYC expression in fully transformed SCL tg LMO1 tg leukemic blasts ( Figure 5I ) and addressed the question of whether 2-ME2 might also inhibit primary SCL tg LMO1 tg leukemic cells. Comparison of the transcriptomes of murine SCL-LMO1-induced T-ALLs and of their normal counterparts points to the regulation of apoptosis as a top gene ontology category among SCL targets (Supplemental Figure 10A ). We observed that 2-ME2 induced apoptosis in vitro both in pre-LSCs and in T-ALL blasts from SCL tg LMO1 tg mice (Supplemental Figure 10B) , consistent with an inhibition of SCL antiapoptotic function (49) (50) (51) .
To study the effect of 2-ME2 on T-ALL in vivo, primary SCL tg LMO1 tg T-ALL blasts were transplanted into 10 syngeneic mice ( Figure 6A ). After engraftment (Supplemental Figure 10C) , which was as rapid and homogenous as in Figure 1E , mice were treated with 2-ME2 via implantation of osmotic minipumps (40 mg/kg/d) ( Figure 6A ). Compared with control mice receiving the vehicle only, 2-ME2 induced a profound reduction of leukemic blasts in the BM, thymus, spleen, and peripheral blood ( Figure 6 , B and C) and altered their capacities to initiate leukemia in secondary recipients ( Figure 6D ). In contrast, the analysis of normal host (CD45.1 + ) T cell compartments indicated that 2-ME2 did not block normal T cell differentiation in vivo (Supplemental Figure 11A) , confirming our in vitro results (Supplemental Figure 4B) . Despite high MYC levels in normal DN3 thymocytes, 2-ME2 did not affect MYC expression levels in these cells (Supplemental Figure 11B) , concurring with their low sensitivities to 2-ME2 ( Figure 3E ). We therefore conclude that the SCL and LMO1 oncogenes sensitize DN3 cells to 2-ME2.
In parallel, we monitored how 2-ME2 affects residual normal stem/progenitor cells in the same mice. Host HSCs can be distinguished from transplanted cells on the basis of CD45 isoforms, as shown in Figure 6A inhibitory effect on MYC. Concurring with the emerging role of MYC in AML (59, 60) , perphenazine, the only phenothiazine hit in AML in the present study, was revealed as a top hit in a chemical screen for suppressors of MYC-induced T-ALL in zebrafish (35) . Finally, the multiparametric screening assay described here could potentially allow for the identification of compounds that restore cell differentiation in T-ALL, as exemplified by the differentiation therapy achieved in acute promyelocytic leukemia (61) . The importance of regulated translation in T-ALL is underscored by the finding of recurring loss-of-function mutations in several ribosomal genes, RPL5, RPL10, and RPL22, in 10%-20% of pediatric T-ALL (62) . In addition, PTEN deletion occurs in 20% of T-ALL, causing increased AKT (63) and a hyperactive mTORC1 pathway. The translation of mRNA into polypeptide is mostly controlled at the level of translation initiation, which is partly regulated by the mTORC1 signaling pathway (47) . While mTORC1 controls global protein synthesis, it preferentially stimulates the translation of selected groups of mRNAs that contain relatively long and structured 5′-UTRs, including MYC (47) . Here, we show that 2-ME2 strongly alters MYC translation without modifying SCL translation. We thus conclude that MYC and SCL have differential dependence on the mTORC1 pathway. It remains to be determined whether this differential dependence could be imparted by the structure of their 5′-UTRs, as reported for MYC (47) . In summary, our observations place MYC as a highly sensitive target hit of 2-ME2, downstream of the mTORC1 pathway. Finally, MYC is frequently dysregulated in tumors and represents a major target in cancer therapy (64) . In addition to inhibiting MYC transcription or activity (65) , our observations support the view that it is possible to target MYC translation.
SCL controls HSC self-renewal activity under stress (50, (66) (67) (68) , and is redundant with Lyl1 during steady-state hematopoiesis (69) . In contrast, SCL activation in thymocytes occurs in a context whereby other self-renewal genes are absent and therefore pre-LSCs are "addicted" to SCL. Along the same line, Lyl1 upregulation by Lmo2 in DN3 thymocytes occurs in a context whereby Scl is not expressed, and therefore Lyl1 is required for Lmo2 reprogramming activity (70) . Similarly, Myc is critical for pre-LSC selfrenewal activity (14, 56) , whereas Myc is redundant in HSCs (71) , indicating that targeting MYC will spare normal HSCs. Our results do not rule out the possibility that normal stem/progenitor cells express a 2-ME2-resistant isoform of tubulin, β 1 -tubulin, proposed to protect patients from drug-induced myelosuppression (72) . Nonetheless, we favor the idea that differential dependence on SCL and MYC levels distinguishes pre-LSCs from normal HSCs. Hence, decreasing SCL and MYC protein levels is synthetic lethal in pre-LSCs but not in HSCs that are endowed with a highly redundant self-renewal node.
Chemical biology combined with the capacity for HTS provides unprecedented opportunities for drug discovery. Yet, despite the number of hits, there is currently a tendency for high drug attrition rates when it comes to efficacy in clinical trials (73) . Without ruling out the possibility that many factors could contribute to this high attrition rate, our results suggest that cell line-based screening as well as 2-dimensional screening assays may not yield muchneeded novel bioactive compounds. While these assays have been useful in identifying anticancer drugs, it is well known that cell an ex vivo assay mimicking a thymic-like microenvironment, and demonstrated the feasibility of this strategy for HTS. This strategy led us to identify an inhibitor that targets 2 central actors of the self-renewal node in pre-LSCs, SCL and MYC (14) .
The development of new drugs targeting self-renewing (pre) cancer stem cells could open new therapeutic opportunities for more selective treatments (6) . In T-ALL, leukemic stem cells are capable of sustained leukemia propagation. Nonetheless, these cells are endowed with an evolving genetic landscape, carrying founder mutations as well as varying secondary mutations (24, 52) . In contrast, the emergence of self-renewing pre-LSCs via oncogene-induced reprogramming of normal thymocytes represents the earliest events in T-ALL (10, 12, 14) and in B cell acute lymphoblastic leukemia (7) . Therefore, pre-LSCs represent the prime cellular target for novel drug development. In AML, these cells are believed to harbor landscaping mutations that remain stable in remission and relapse (4) . These molecular studies also suggested that the cells that caused relapse are preleukemic HSCs that do not have the full complement of transforming events. Obviously, these cells must have escaped therapy (4). Nonetheless, direct evidence for differential chemosensitivity between pre-LSCs and leukemic blasts was hindered by the extreme rarity of these cells within the tumor bulk, as we now show that pre-LSCs are rapidly offset by more competitive, fully transformed leukemic blasts. We took advantage of the mouse model that recapitulates the evolution of the human disease to demonstrate that pre-LSCs are less sensitive than leukemic blasts to drugs that target proliferating cells, such as topoisomerase inhibitors, because of their low proliferative status. Similarly, leukemic blasts and pre-LSCs also exhibit differential sensitivities to radiation (54) .
Our previous work indicates that self-renewing pre-LSCs depend both on the primary oncogenes and on the physiological NOTCH1 pathway activated by the microenvironment (14) . Interestingly, 2-ME2 specifically prevents SCL accumulation via a colchicine-independent mechanism, which differs from the colchicine-sensitive transport of HIF-1α into the nucleus via microtubules (36) . Moreover, 2-ME2 also decreased MYC protein levels, resulting in decreased expression of a prototypic MYC target gene, ODC. Based on our previous finding that MYC can substitute for NOTCH1 signaling to collaborate with SCL-LMO1 in thymocyte reprogramming (14) , we conclude that 2-ME2 inhibits pre-LSCs by antagonizing their dependence on both SCL and the DL4-NOTCH1 pathway. Moreover, we showed that 2-ME2 inhibits SCL and MYC targets in primary human T-ALL blasts and prevents their growth in a preclinical model of T-ALL.
Interestingly, gain of function of NOTCH1 is the most frequent genetic alteration in T-ALL that can be found in all molecular subgroups, defined by SCL/TAL1, LMO2, TLX1/3, HOXA, and MYB (9, 26, 55) . Given the necessary collaboration of NOTCH1-MYC with SCL-LMO1 in self-renewing pre-LSCs (14) and the importance of NOTCH1-MYC in T-ALL (56, 57) , we surmise that inhibiting MYC could be lethal in other molecular T-ALL subgroups. In addition, inhibition of the NOTCH signaling pathway can antagonize glucocorticoid resistance, an adverse prognostic factor in ALL (58) . We propose that 2-ME2 will be beneficial for the treatment of glucocorticoid-resistant primary or relapsed human T-ALL. In addition, 2-ME2 may be of interest in AML treatment as well because of its jci.org Volume 126 Number 12 December 2016
APC-anti-CD8, PE-Cy7-anti-CD25, and AF780-anti-CD44 at 4°C for 15 minutes. The screen was then performed with an LSRII flow cytometer equipped with an HTS module (BD Biosciences). FACS analysis and cell sorting. Immunostaining was done as previously described (33) . Dead cells were excluded by propidium iodide staining. Immunophenotype and apoptosis analysis was performed on an LSRII cytometer using DIVA (BD Biosciences) software. Cell sorting was done using an FACSAria cytometer (BD Biosciences).
Congenic transplantation assay. Preleukemic thymocytes from donor mice (CD45.2 + ) were transplanted in i.v. into sublethally irradiated (600 cGy) recipient mice (CD45.1 + ) (14) . Thymic chimerism in the T lineage (Thy1.2 + ) was analyzed by flow cytometry (FACS) and illustrated by the percentage of donor-derived cells (% CD45.2 + ) found in the recipient thymus.
In vivo study of the effect of 2-ME2 on T-ALL development and HSC functions. T-ALL blasts (CD45.2 + ) from primary SCL tg LMO1 tg thymoma were injected i.v. into 10 sublethally irradiated CD45.1 + recipient mice (5 × 10 6 blasts per mouse). T-ALL reconstitution was assessed by FACS after BM aspiration, and mice were randomly selected for treatment with vehicle alone (50% DMSO; 50% PEG400) or 2-ME2 (Bosche Scientific, M19071; 40 mg/kg/d). Osmotic minipumps (Alzet model 2001; 1 μl/h, 7 days) containing vehicle or 2-ME2 were loaded and primed at 37°C in 0.9% NaCl, 24 hours before their subcutaneous implantation, in accordance with the manufacturer's instructions. T-ALL reconstitution was monitored in the thymus, BM, spleen, and blood, and engrafted T-ALL blasts from the BM were transplanted into secondary sublethally irradiated CD45.1 + mice. c-Kit + Sca-1 + lineage -(KSL) cells from the BM of treated CD45.1 + mice were transplanted into secondary lethally irradiated CD45.2 + mice in parallel.
Xenogenic transplantation assay. T-ALL patient samples were selected for high blast counts (>90%) in the peripheral blood. T-ALL blasts were immunophenotyped using FITC-anti-hCD45, PE-anti-hCD7, PE-Cy7-anti-hCD4, PE-Cy5-anti-hCD8, and APC-anti-hCD34. Normal peripheral CD34 + CD7hematopoietic progenitors and mature CD4 +/hi and CD8 +/hi single-positive T cells (28) were excluded by cell sorting, and T-ALL blasts were transplanted and expanded by transplantation into sublethally irradiated (250 cGy) 8to 12-week-old NOD-Scid IL2rg null mice (NSG, Jackson Laboratory).
Engrafted T-ALL blasts were collected from the spleen and the BM 6-8 weeks after transplantation.
T-ALL blasts (CD45 + CD7 + ) from primary NSG mice engrafted with each patient sample were injected i.v. into 10 secondary NSG mice (5 × 10 6 blasts per mouse). T-ALL reconstitution was assessed by FACS after BM aspiration, and mice were randomly selected for treatment with the vehicle or 2-ME2 using osmotic minipumps as described above.
Limiting dilution assays. Preleukemic thymocytes were transplanted into irradiated hosts at various cell doses. Mice were scored positive when T cell lineage reconstitution was more than 0.1% in the thymus. Pre-LSCs frequencies (range pre-LSC ± CI), also named competitive repopulating unit frequencies, were calculated by application of Poisson statistics using Limiting Dilution Analysis software (Stem Cell Technologies) (66) .
Metabolic radiolabeling with 35 S-methionine and immunoprecipitation. 4 × 10 7 JURKAT cells (10 6 cells/ml) were incubated overnight at 37°C, washed twice with 50 ml of l-methionine-free DMEM (Wisent Inc., 319-045-CL), and pretreated or not (DMSO) with 2-ME2 (3 μM) for 30 minutes. Cells were then centrifuged to fate is shaped by the local niche. It is therefore not surprising that the niche may also modify the chemosensitivity of primary leukemic blasts (74) . Our strategy led to the identification of a drug that inhibits both cell-autonomous and non-cell-autonomous pathways, acting in vitro and in vivo, while sparing normal HSCs. We propose that recapitulating tissue-like conditions (75) (76) (77) represents a promising avenue in the quest for new cancer therapies in other tumors.
Methods
Supplemental Methods are available online with this article; doi:10.1172/JCI86489DS1.
Human leukemia samples and cell lines. All AML and T-ALL samples were collected from the Maisonneuve-Rosemont Hospital of Montreal, Canada. Human JURKAT, KOPTK1, P12-ICHIKAWA, and HPB-ALL cell lines were obtained from DSMZ, Germany.
Mice and ethics statement. All animals were maintained in pathogen-free conditions. The current study was performed using previously described SIL-SCL (referred to as SCL tg ) and Lck-LMO1 (referred to as LMO1 tg ) mice (15, 16, 33) . All mouse lines were backcrossed onto a C57BL6/J background for more than 12 generations. Mice cohorts were generated by cross-breeding, and their genotypes were verified by PCR.
Generation of MS5-DL4 stromal cell lines. Mouse stromal MS5 cells than can maintain in vitro both mouse and human long-term hematopoiesis were from K. Mori (Nagata University, Japan) (78) and were maintained as described previously (30) . VSV-G-producing cells transfected with the human DLL4 cDNA (MHS4426-98361330, GE Healthcare) were used for gene transduction in MS5 cells (48 hours) as described previously (50, 66) . Transduced MS5 cells were stained using rabbit anti-DLL4 (ab7280, Abcam), and 3 MS5 stromal cell lines were generated by cell sorting according to 3 levels of DL4 expression (low, medium, and high). Staining with the secondary antibody only was used for negative controls.
Chemical screen of small molecules on pre-LSCs. MS5-DL4 stromal cells (2 × 10 3 per 40 μl per well) were seeded in 384-well plates in complete T cell medium described in the Supplemental Methods. Twenty-four hours later, DN thymocytes from thymi of 3-week-old preleukemic SCL tg LMO1 tg mice were prepared by depletion of CD4 + and CD8 + thymocytes through immunomagnetic bead cell separation as previously described (66) . DN3 (pre-LSC) thymocytes (5 × 10 3 per 5 μl per well) were then purified and cocultured on seeded MS5-DL4 stromal cells by cell sorting. Twenty-four hours later, cocultured pre-LSCs were exposed to 1,904 individual FDA-approved and drug-like small molecules (Preswick; Biomol; Lopac/Sigma-Aldrich; Micro-Source Discovery Systems) at a dose of 500 nM. Absolute numbers of DN3 cells were determined after 5 days of culture using flow cytometry. In each plate, 16 wells containing pre-LSCs were treated with 1 μM γ-secretase inhibitor (GSI) and 16 wells were treated with DMSO (vehicle) as positive and negative controls, respectively (Supplemental Figure 2 ). The inhibition (percentage) of pre-LSC viability by individual compounds was calculated based on the absolute numbers of cells in the DN3 gate (Thy1 + CD4 -CD8 -CD25 + CD44 -) recovered from 3 different treatment conditions according to the formula 100 -((test compound -median GSI) / (median vehicle -median GSI) × 100).
Pre-LSCs were stained by addition of 5 μl/well of PBS supplemented with 2% FBS containing PE-anti-Thy1.2, PE-Cy5-anti-CD4,
